A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma
NCT ID: NCT06656039
Last Updated: 2024-10-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1200 participants
OBSERVATIONAL
2024-01-01
2024-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A CT-BASED Deep Learning Model for Predicting WHO/ISUP Pathological Grades of Clear Cell Renal Cell Carcinoma (ccRCC) :A Multicenter Cohort Study
NCT06559046
Multiomics Approach in Metastatic Clear Renal Cell Carcnoma
NCT05782400
Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning
NCT07332923
Optimising Renal Tumour Management Through Artificial Intelligence Modules
NCT06714916
Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma
NCT06111560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Training cohort
No interventions assigned to this group
Validation cohort
No interventions assigned to this group
Test cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have available preoperative imaging
* Have available post-operative pathological paraffin samples or HE-stained tissue sections
* Must agree to and be able to comply with the study's visit schedule and other requirements as specified in the protocol, including follow-up visits by telephone
Exclusion Criteria
* Simultaneous combination of primary tumours at other sites;
* No regular follow-up imaging data
* Cases in which other factors led the investigator to believe that enrolment was inappropriate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of Anhui Medical University
OTHER
The Fourth Affiliated Hospital of Harbin Medical University
OTHER
Second Affiliated Hospital of Soochow University
OTHER
Qianfoshan Hospital
OTHER
Chang Gung Memorial Hospital
OTHER
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ccRCC MRPS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.